Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 37 to 40 of 40 entries
Sorted by: Best Match Show Resources per page
[Clinical features and risk factors associated with prenatal exposure to drugs of abuse].

Anales de pediatria

Roca A, Jarque P, Gomila I, Marchei E, Tittarelli R, Elorza MÁ, Sanchís P, Barceló B.
PMID: 33041240
An Pediatr (Engl Ed). 2020 Oct 08; doi: 10.1016/j.anpedi.2020.08.003. Epub 2020 Oct 08.

INTRODUCTION: Early identification of neonates exposed to drugs of abuse during pregnancy allows a more precise clinical management.OBJECTIVES: To describe the clinical characteristics and to identify risk factors associated with the early detection of neonates exposed to drugs of...

Cite
Roca A, Jarque P, Gomila I, et al. Características clínicas y factores de riesgo asociados a la exposición prenatal a drogas de abuso. [Clinical features and risk factors associated with prenatal exposure to drugs of abuse]. An Pediatr (Engl Ed). 2020;doi: 10.1016/j.anpedi.2020.08.003.
Roca, A., Jarque, P., Gomila, I., Marchei, E., Tittarelli, R., Elorza, M. �. �., Sanchís, P., & Barceló, B. (2020). Características clínicas y factores de riesgo asociados a la exposición prenatal a drogas de abuso. [Clinical features and risk factors associated with prenatal exposure to drugs of abuse]. Anales de pediatria, . https://doi.org/10.1016/j.anpedi.2020.08.003
Roca, Antonia, et al. "Características clínicas y factores de riesgo asociados a la exposición prenatal a drogas de abuso." [Clinical features and risk factors associated with prenatal exposure to drugs of abuse]. Anales de pediatria vol. (2020). doi: https://doi.org/10.1016/j.anpedi.2020.08.003
Roca A, Jarque P, Gomila I, Marchei E, Tittarelli R, Elorza MÁ, Sanchís P, Barceló B. Características clínicas y factores de riesgo asociados a la exposición prenatal a drogas de abuso. [Clinical features and risk factors associated with prenatal exposure to drugs of abuse]. An Pediatr (Engl Ed). 2020 Oct 08; doi: 10.1016/j.anpedi.2020.08.003. Epub 2020 Oct 08. Spanish. PMID: 33041240.
Copy Download .nbib Format: NLM
Eltrombopag Added to Immunosuppression in Severe Aplastic Anemia.

The New England journal of medicine

Peffault de Latour R, Kulasekararaj A, Iacobelli S, Terwel SR, Cook R, Griffin M, Halkes CJM, Recher C, Barraco F, Forcade E, Vallejo JC, Drexler B, Mear JB, Smith AE, Angelucci E, Raymakers RAP, de Groot MR, Daguindau E, Nur E, Barcellini W, Russell NH, Terriou L, Iori AP, La Rocca U, Sureda A, Sánchez-Ortega I, Xicoy B, Jarque I, Cavenagh J, Sicre de Fontbrune F, Marotta S, Munir T, Tjon JML, Tavitian S, Praire A, Clement L, Rabian F, Marano L, Hill A, Palmisani E, Muus P, Cacace F, Frieri C, van Lint MT, Passweg JR, Marsh JCW, Socié G, Mufti GJ, Dufour C, Risitano AM.
PMID: 34986284
N Engl J Med. 2022 Jan 06;386(1):11-23. doi: 10.1056/NEJMoa2109965.

BACKGROUND: A single-group, phase 1-2 study indicated that eltrombopag improved the efficacy of standard immunosuppressive therapy that entailed horse antithymocyte globulin (ATG) plus cyclosporine in patients with severe aplastic anemia.METHODS: In this prospective, investigator-led, open-label, multicenter, randomized, phase 3...

Cite
Peffault de Latour R, Kulasekararaj A, Iacobelli S, et al. Eltrombopag Added to Immunosuppression in Severe Aplastic Anemia. N Engl J Med. 2022;386(1):11-23doi: 10.1056/NEJMoa2109965.
Peffault de Latour, R., Kulasekararaj, A., Iacobelli, S., Terwel, S. R., Cook, R., Griffin, M., Halkes, C. J. M., Recher, C., Barraco, F., Forcade, E., Vallejo, J. C., Drexler, B., Mear, J. B., Smith, A. E., Angelucci, E., Raymakers, R. A. P., de Groot, M. R., Daguindau, E., Nur, E., Barcellini, W., Russell, N. H., Terriou, L., Iori, A. P., La Rocca, U., Sureda, A., Sánchez-Ortega, I., Xicoy, B., Jarque, I., Cavenagh, J., Sicre de Fontbrune, F., Marotta, S., Munir, T., Tjon, J. M. L., Tavitian, S., Praire, A., Clement, L., Rabian, F., Marano, L., Hill, A., Palmisani, E., Muus, P., Cacace, F., Frieri, C., van Lint, M. T., Passweg, J. R., Marsh, J. C. W., Socié, G., Mufti, G. J., Dufour, C., Risitano, A. M. (2022). Eltrombopag Added to Immunosuppression in Severe Aplastic Anemia. The New England journal of medicine, 386(1), 11-23. https://doi.org/10.1056/NEJMoa2109965
Peffault de Latour, Régis, et al. "Eltrombopag Added to Immunosuppression in Severe Aplastic Anemia." The New England journal of medicine vol. 386,1 (2022): 11-23. doi: https://doi.org/10.1056/NEJMoa2109965
Peffault de Latour R, Kulasekararaj A, Iacobelli S, Terwel SR, Cook R, Griffin M, Halkes CJM, Recher C, Barraco F, Forcade E, Vallejo JC, Drexler B, Mear JB, Smith AE, Angelucci E, Raymakers RAP, de Groot MR, Daguindau E, Nur E, Barcellini W, Russell NH, Terriou L, Iori AP, La Rocca U, Sureda A, Sánchez-Ortega I, Xicoy B, Jarque I, Cavenagh J, Sicre de Fontbrune F, Marotta S, Munir T, Tjon JML, Tavitian S, Praire A, Clement L, Rabian F, Marano L, Hill A, Palmisani E, Muus P, Cacace F, Frieri C, van Lint MT, Passweg JR, Marsh JCW, Socié G, Mufti GJ, Dufour C, Risitano AM. Eltrombopag Added to Immunosuppression in Severe Aplastic Anemia. N Engl J Med. 2022 Jan 06;386(1):11-23. doi: 10.1056/NEJMoa2109965. PMID: 34986284.
Copy Download .nbib Format: NLM
Survivin drives tumor-associated macrophage reprogramming: a novel mechanism with potential impact for obesity.

Cellular oncology (Dordrecht)

Benaiges E, Ceperuelo-Mallafré V, Madeira A, Bosch R, Núñez-Roa C, Ejarque M, Maymó-Masip E, Huber-Ruano I, Lejeune M, Vendrell J, Fernández-Veledo S.
PMID: 33710603
Cell Oncol (Dordr). 2021 Aug;44(4):777-792. doi: 10.1007/s13402-021-00597-x. Epub 2021 Mar 12.

PURPOSE: Recent studies point to adipose-derived stem cells (ASCs) as a link between obesity and cancer. We aimed to determine whether survivin, which is highly secreted by ASCs from subjects with obesity, might drive a pro-tumoral phenotype in macrophages.METHODS:...

Cite
Benaiges E, Ceperuelo-Mallafré V, Madeira A, et al. Survivin drives tumor-associated macrophage reprogramming: a novel mechanism with potential impact for obesity. Cell Oncol (Dordr). 2021;44(4):777-792doi: 10.1007/s13402-021-00597-x.
Benaiges, E., Ceperuelo-Mallafré, V., Madeira, A., Bosch, R., Núñez-Roa, C., Ejarque, M., Maymó-Masip, E., Huber-Ruano, I., Lejeune, M., Vendrell, J., & Fernández-Veledo, S. (2021). Survivin drives tumor-associated macrophage reprogramming: a novel mechanism with potential impact for obesity. Cellular oncology (Dordrecht), 44(4), 777-792. https://doi.org/10.1007/s13402-021-00597-x
Benaiges, E, et al. "Survivin drives tumor-associated macrophage reprogramming: a novel mechanism with potential impact for obesity." Cellular oncology (Dordrecht) vol. 44,4 (2021): 777-792. doi: https://doi.org/10.1007/s13402-021-00597-x
Benaiges E, Ceperuelo-Mallafré V, Madeira A, Bosch R, Núñez-Roa C, Ejarque M, Maymó-Masip E, Huber-Ruano I, Lejeune M, Vendrell J, Fernández-Veledo S. Survivin drives tumor-associated macrophage reprogramming: a novel mechanism with potential impact for obesity. Cell Oncol (Dordr). 2021 Aug;44(4):777-792. doi: 10.1007/s13402-021-00597-x. Epub 2021 Mar 12. PMID: 33710603; PMCID: PMC8338861.
Copy Download .nbib Format: NLM
Multidisciplinary approach to the treatment of invasive fungal infections in adult patients. Prophylaxis, empirical, preemptive or targeted therapy, which is the best in the different hosts?.

Therapeutics and clinical risk management

Zaragoza R, Pemán J, Salavert M, Viudes A, Solé A, Jarque I, Monte E, Romá E, Cantón E.
PMID: 19337433
Ther Clin Risk Manag. 2008 Dec;4(6):1261-80. doi: 10.2147/tcrm.s3994.

The high morbidity, mortality, and health care costs associated with invasive fungal infections, especially in the critical care setting and immunocompromised host, have made it an excellent target for prophylactic, empiric, and preemptive therapy interventions principally based on early...

Cite
Zaragoza R, Pemán J, Salavert M, et al. Multidisciplinary approach to the treatment of invasive fungal infections in adult patients. Prophylaxis, empirical, preemptive or targeted therapy, which is the best in the different hosts?. Ther Clin Risk Manag. 2008;4(6):1261-80doi: 10.2147/tcrm.s3994.
Zaragoza, R., Pemán, J., Salavert, M., Viudes, A., Solé, A., Jarque, I., Monte, E., Romá, E., & Cantón, E. (2008). Multidisciplinary approach to the treatment of invasive fungal infections in adult patients. Prophylaxis, empirical, preemptive or targeted therapy, which is the best in the different hosts?. Therapeutics and clinical risk management, 4(6), 1261-80. https://doi.org/10.2147/tcrm.s3994
Zaragoza, Rafael, et al. "Multidisciplinary approach to the treatment of invasive fungal infections in adult patients. Prophylaxis, empirical, preemptive or targeted therapy, which is the best in the different hosts?." Therapeutics and clinical risk management vol. 4,6 (2008): 1261-80. doi: https://doi.org/10.2147/tcrm.s3994
Zaragoza R, Pemán J, Salavert M, Viudes A, Solé A, Jarque I, Monte E, Romá E, Cantón E. Multidisciplinary approach to the treatment of invasive fungal infections in adult patients. Prophylaxis, empirical, preemptive or targeted therapy, which is the best in the different hosts?. Ther Clin Risk Manag. 2008 Dec;4(6):1261-80. doi: 10.2147/tcrm.s3994. PMID: 19337433; PMCID: PMC2643107.
Copy Download .nbib Format: NLM
Showing 37 to 40 of 40 entries